Chief Regulatory and Safety Officer · Kalaris Therapeutics, Inc. (KLRS)

Ercem Atillasoy

FY2020 is the first fiscal year CompBrief holds for Ercem Atillasoy as a named executive officer of Kalaris Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$6,918,172

Salary $172,949Stock awards $1,275,000

2nd of 3 named executive officers at Kalaris Therapeutics by FY2020 total.

3 named officers on file for Kalaris Therapeutics, FY2020

Ercem Atillasoy’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kalaris Therapeutics’s whole pay program stands against its peers

  • Kalaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KLRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 12, 2021 (DEF 14A).

Free

Get Ercem Atillasoy’s full pay file as a PDF — free

More than this page: up to 10 years of Ercem’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Ercem Atillasoy compensation by year

Kalaris Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Kalaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$172,949
Bonus$0
Stock awards$1,275,000
Option awards$5,283,089
Non-equity incentive$187,134
Pension and deferred compensation$0
All other$0
Total$6,918,172

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kalaris Therapeutics, Inc. DEF 14A filed April 12, 2021, accession 0001193125-21-113152, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kalaris Therapeutics, Inc. filed document, accession 0001193125-21-113152. Every figure is read from that document and cited to the page and table it appears in. Filed April 12, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU75,000$2,883,000—
Option407,400—$17.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Kalaris Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Kalaris Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
David HallalChief Executive Officer and Chairman$15,258,586
Ercem Atillasoy · this pageChief Regulatory and Safety Officer$6,918,172
Vikas SinhaPresident and Chief Financial Officer$6,320,540

The full Kalaris Therapeutics compensation record

free company brief

This page is one person within Kalaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kalaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ercem Atillasoy's compensation dossier · One-time report. No refunds.